Skip to content

Sudden increases in viral load in first two years of infection could indicate superinfection

Kenya: treatment literacy lagging behind ARV rollout

Past treatment with amprenavir/fosamprenavir associated with presence of resistance that can reduce susceptibility to darunavir

ICAAC: Cross-resistance to 3TC and FTC develops slowly with entecavir monotherapy

ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance

Virologically failing NNRTI regimens have higher resistance risk than failing boosted-PIs

Pillboxes should be standard issue for HIV patients, study concludes

HIV/HBV coinfected patients should not take entecavir unless on anti-HIV treatment due to resistance risk

IAS: Maraviroc produces best results when combined with another active drug